MDxHealth (NASDAQ:MDXH – Get Rating) and Quest Diagnostics (NYSE:DGX – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Earnings & Valuation
This table compares MDxHealth and Quest Diagnostics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|MDxHealth||$37.05 million||1.27||-$44.04 million||($1.90)||-1.52|
|Quest Diagnostics||$9.88 billion||1.48||$946.00 million||$7.92||16.61|
Quest Diagnostics has higher revenue and earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
12.6% of MDxHealth shares are owned by institutional investors. Comparatively, 88.8% of Quest Diagnostics shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 1.7% of Quest Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for MDxHealth and Quest Diagnostics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
MDxHealth presently has a consensus target price of $12.00, indicating a potential upside of 315.22%. Quest Diagnostics has a consensus target price of $150.91, indicating a potential upside of 14.73%. Given MDxHealth’s stronger consensus rating and higher possible upside, research analysts plainly believe MDxHealth is more favorable than Quest Diagnostics.
Risk & Volatility
MDxHealth has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.
Quest Diagnostics beats MDxHealth on 10 of the 12 factors compared between the two stocks.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
About Quest Diagnostics
Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.